Essential Pharma Group https://validator.w3.org/feed/docs/rss2.html Simon Ball Medical Science Liaison France Homepage About us Corporate Responsibility Essential Pharma Appoints Ben Ash as Chief Financial Officer Becki Morison Regulatory Lead – CNS & Ophthalmology Careers Regulatory Lead – Infectious Disease & Internal Medicine Contact us Essential Pharma strengthens rare disease portfolio with acquisition of Ventavis® (iloprost trometamol) for adult primary pulmonary hypertension Q&A with Jonathan Koneswaran, Employee spotlight September 2025 Renaissance Pharma Limited, an Essential Pharma company, secures FDA Fast Track Designation and IND clearance for Daretabart (hu1418K322A) in high-risk neuroblastoma Partnering Essential Pharma Group Entities Q&A with Erica Fazakerley, Employee spotlight December 2025 Q&A with Luke Lee, Associate Director, M&A Medical Science Liaison UK & France Q&A with Jayshree Jadeja, Employee spotlight October 2025 Product Specialist France Product Specialist Spain Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team Essential Pharma Embarks on New Era of Growth Following Management Buy Out Supported by Gyrus Capital Lewis Pearson Products Privacy Policy Modern Slavery Policy Legal Notice Cookie Policy Rob Smith Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director Latest News and Events Andrew Webb Clinical Development Associate Director Guy Semmens Jefferies Global Healthcare Conference CPHI Frankfurt Jeff Pootoolal Simon Ramsden Gursharan Randhawa Jonathan Arnold Dr Robert Watson Lee Morley Helen Stephenson-Ellis Essential Pharma Appoints Ingvild Liborg As Chief Executive Officer Essential Pharma appoints Becki Morison as Chief Executive Officer Essential Pharma Welcomes Swift and Successful Conclusion of CMA Priadel Inquiry Essential Pharma Appoints Pharma and Healthcare Operations Expert Colin Brown As Chief Operating Officer Nicola Heffron